Verve Therapeutics Inc. has released its financial results for the first quarter of 2025, showing a substantial increase in collaboration revenue, which reached $33.0 million compared to $5.7 million in the first quarter of 2024. This increase was primarily attributed to the recognition of remaining deferred revenue from the research collaboration with Vertex Pharmaceuticals, following Vertex's notification of termination, as well as increased recognition of amounts related to research services under the collaboration with Lilly. The company reported a net loss of $31.0 million for the first quarter of 2025, an improvement from the $48.7 million net loss reported for the same period in 2024. Research and development expenses rose to $54.5 million from $48.4 million in the previous year, and general and administrative expenses increased slightly to $15.2 million from $14.2 million. Verve Therapeutics also announced pipeline progress, including positive initial data from its Heart-2 Phase 1b clinical trial of VERVE-102, which demonstrated dose-dependent decreases in blood LDL-C and PCSK9. The trial showed a mean reduction in LDL-C of 53%, with a maximum reduction of 69% observed after a single infusion of VERVE-102 in the 0.6 mg/kg dose cohort. Additionally, the Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 continues to progress, with an update expected in the second half of 2025. The company's cash, cash equivalents, and marketable securities were $497.1 million as of March 31, 2025, compared to $524.3 million as of December 31, 2024, and Verve expects its capital position to be sufficient to fund operations into mid-2027.